Citations

Clear

2303 citation(s) found for "Yu, Edward".

Transforming Growth Factor Beta Induces Fibroblasts to Express and Release the Immunomodulatory Protein PD‐L1 into Extracellular Vesicles
Leof, Edward B. , Kang, Jeong Han , Jung, Mi‐Yeon

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 33 | Issue: S1 | Pages: No page available

10.1096/fasebj.2019.33.1_supplement.476.12 Get It

Transforming growth factor beta (TGF‐β) is an enigmatic protein with various roles in normal tissue homeostasis/development as well as the development and/or progression of cancer, wound healing, fibrotic disorders, and immune modulation, to name a few. As TGF‐β is causal to various fibroproliferative disorders featuring localized or systemic tissue/organ fibrosis as well as the activated stroma observed in numerous malignancies, characterizing the pathways and players mediating its action is fundamental. To that end, in the current study we found that (i) TGF‐β induces the expression of the immunoinhibitory molecule Programmed Death‐Ligand 1 (PD‐L1) in human and murine fibroblasts in a Smad2/3‐dependent manner; (ii) profibrotic TGF‐β signaling is dependent upon PD‐L1 expression; and (iii) following treatment with TGF‐β, human lung fibroblasts secrete PD‐L1 into extracellular vesicles (EVs) capable of inhibiting T‐cell proliferation in response to T cell receptor stimulation. These findings provide new insights and potential targets for a variety of fibrotic and/or malignant diseases. Support or Funding Information This work was supported by Public Health Service grants GM‐55816 and GM‐54200 from the National Institute of General Medical Sciences. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Abstract 68: Impaired Perfusion in Intracranial Atherosclerotic Disease Predicts Cognitive Outcomes
Cotsonis, George, Yaghi, Shadi , Honda, T , Scalzo, Fabien , Cloft, Harry J. , Feldmann, Edward, Investigators, for the SAMMPRIS, Liebeskind, David S. , Romano, José G. , Fiorella, David , Derdeyn, Colin P. , Prabhakaran, Shyam , Investigators, for the SAMMPRIS

Mayo Clinic

Stroke | June 21, 2021 | Volume: 51 | Issue: Suppl_1 | Pages: No page available

10.1161/str.51.suppl_1.68 Get It

Background: Poor collateral circulation and hypoperfusion may lead to recurrent stroke in intracranial atherosclerotic disease (ICAD). The role of perfusion in silent strokes and potentially insidious cognitive impairment in ICAD is unknown. We used evidence of impaired perfusion at angiography in SAMMPRIS to predict subsequent cognitive changes. Methods: Angiography at enrollment in the SAMMPRIS trial was independently evaluated, blind to clinical data and cognitive testing. Antegrade flow in the symptomatic arterial territory and corresponding collateral flow were scored. Impaired perfusion was defined by poor antegrade and poor collateral flow. Serial testing with the Montreal Cognitive Assessment (MoCA) was done in subjects without aphasia or neglect at baseline, 4 mo, 12 mo and closeout, or until subjects had a clinical stroke endpoint. Results: 207 subjects (median age 61, range 33-81 years; 37% women) had baseline MoCA scores with angiography data on territorial perfusion. Baseline MoCA scores (mean 24.2±4.1) were similar between categories of antegrade flow and collateral circulation. Impaired perfusion was noted in 33/207 (16%). Serial MoCA revealed that changes in cognition over time were different at 4 mo, 12 mo and closeout based on the presence of impaired perfusion at baseline (p<0.001). After more modest (mean MoCA change = 0.5 increase from baseline, p=0.80) early improved cognitive function at 4 mo, those with impaired perfusion had cognitive decline at 12 mo (mean MoCA change, p<0.01) unlike the continued improvement in other subjects. Cognitive changes in those with impaired perfusion were associated with a higher frequency of subsequent stroke in the territory. Conclusions: Impaired perfusion in the symptomatic arterial territory of ICAD predicts cognitive outcomes that may precede recurrent ischemia. Future studies may define the role of noninvasive perfusion imaging in ICAD to predict cognitive trajectories and recurrent stroke.
+ACA BRCA1 promoter polymorphism genotypic frequency among unaffected individuals and breast disease patients
White, Kristen , Basta, Patricia V. , Booker, Jessica K., Highsmith, W. Edward, Tsongalis, Gregory J. , Millikan, Robert C., Coleman, William B.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 23 | Issue: S1 | Pages: No page available

10.1096/fasebj.23.1_supplement.925.9 Get It

We previously identified a +ACA polymorphism at ‐600 bp in the BRCA1 promoter that creates a FAC1 transcriptional repressor binding site. Subsequently, we performed a genotyping study to determine the prevalence of this BRCA1 promoter polymorphism among unaffected individuals and patients with breast disease. The genotypic distribution of the BRCA1 promoter was determined for 997 unaffected individuals and 763 patients with breast disease from the Mayo Clinic, UNC Hospitals, and the Carolina Breast Cancer Study. The BRCA1 promoter genotypic frequency among unaffected individuals was 481/997 (48%) WT/WT, 432/997 (43%) WT/ACA, and 91/997 (9%) ACA/ACA. The BRCA1 promoter genotypic frequency among patients with breast disease was 348/763 (46%) WT/WT, 343/763 (45%) WT/ACA, and 72/763 (9%) ACA/ACA. No differences were noted in the genotypic distribution of the BRCA1 promoter among patients with DCIS, BRCA1 mutation, suspected BRCA1‐related cancer (BRCAx), or sporadic breast cancer. The allelic frequency of the +ACA BRCA1 promoter polymorphism among breast disease groups [343/415 (83%) WT/ACA and 72/415 (17%) ACA/ACA] were not different than the allelic frequency of the controls [432/523 (83%) WT/ACA and 91/523 (17%) ACA/ACA]. Our results suggest that the +ACA BRCA1 promoter polymorphism occurs commonly, and may contribute to breast cancer upon activation of the FAC1 repressor protein. Support: NIH CA78343.
Inositol hexaphosphate alters mucin expression in the intestinal mucosa of mice
Madsen, Cathy S., Gendler, Sandra , Onyango, Edward

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 22 | Issue: S1 | Pages: No page available

10.1096/fasebj.22.1_supplement.1189.8 Get It

Inositol hexaphosphate (IP6 or phytic acid) is thought to be the active ingredient in legumes and cereals that provides anti‐cancer activity. Our goal is to understand the influence of IP6 on mucin expression (Muc1 and Muc2, specifically) in the mouse intestine. C57BL/6 mice were randomized into 3 groups of 6 mice. Mice were orally dosed with IP6 (0, 1, 2 g/kg BW) for 5 days and sacrificed on the sixth day. Sections of the small intestine were removed, fixed in methacarn, sectioned and stained with Alcian blue‐PAS to visualize mucins. Mucosa from the jejunum and colon were removed and total RNA prepared using Trizol®. cDNA was prepared using random hexamers and TaqMan minor groove binding probes were used for real time PCR amplification of message for Muc1 and Muc2. Expression of Muc1 in the jejunum was minimal whereas that of Muc2 increased 1.4‐fold at the higher IP6 dose rate. In the colon, expression of both Muc1 and Muc2 increased in mice dosed with IP6. Expression of Muc1 increased 1.6‐fold and 3.8‐fold in mice dosed with 1 and 2 g/kg IP6, respectively. Expression of Muc2 increased 2.0‐fold and 1.7‐fold in mice dosed with 1 and 2 g/kg IP6, respectively. Alcian blue‐PAS stained sections of the colon showed an increase in mucus. Thus, IP6 seems to increase the expression of Muc1 and Muc2 in the mucosa lining of the small intestine, particularly in the colon. Research was supported by East Tennessee State University and Mayo Clinic.
An Association between Type Igamma PtIns4P 5‐Kinase and Exo70 Directs E‐cadherin Clustering and Epithelial Polarization
Xiong, Xunhao, Xu, Qingwen , Anderson, Richard B. , Leof, Edward B. , Hu, Jinghua , Ling, Kun , Huang, Yan , Singh, Raman Deep , Anderson, Richard

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 26 | Issue: S1 | Pages: No page available

10.1096/fasebj.26.1_supplement.1152.14 Get It

The mechanisms underlying E‐cadherin clustering and AJ maturation are not fully understood although the E‐cadherin‐mediated formation of adherens junctions (AJs) is essential for the morphogenesis of epithelial cells. Here we report that the association between type Iγ phosphatidylinositol phosphate kinase (PIPKIγ) and Exo70 regulated the transport and clustering of Ecadherin on the plasma membrane and, subsequently, the extension of nascent E‐cadherin adhesions. We also observed that PI4,5P(2) accumulation at E‐cadherin clusters during the assembly of E‐cadherin adhesions. PIPKIγ‐generated PI4,5P(2) is required for recruiting Exo70 to newly formed E‐cadherin junctions and facilitates the assembly and maturation of AJs. Additionally, Rho activity and actin structure were impaired by loss of Exo70 and/or PIPKIγ. These results support a model in which PIPKIγ and PIPKIγ‐generated PI4,5P(2) pools at nascent E‐cadherin contacts cue Exo70 targeting and orients the tethering of exocyst‐associated E‐cadherin. This could be an important mechanism that regulates E‐cadherin clustering and AJ maturation, and actin reorganization, which is essential for the establishment of solid, polarized epithelial structures.
Ligand‐Mediated Mitochondrial Translocation of the Transforming Growth Factor‐β Type I Receptor and Hexokinase 2
Yin, Xueqian , Andrianifahanana, Mahefatiana, Leof, Edward B. , Kang, Jeong Han , Jung, Mi‐Yeon, Choudhury, Malay

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 32 | Issue: S1 | Pages: No page available

10.1096/fasebj.2018.32.1_supplement.533.3 Get It

Transforming growth factor beta (TGF‐β) plays a significant role in diverse biologic processes, including the regulation of cell growth, survival, differentiation, development, inflammation, immunity, hematopoiesis, and tissue remodeling. TGF‐β is essential for wound healing, stimulates matrix molecule deposition, and has been implicated in the pathogenesis of a variety of fibrotic disorders, including idiopathic pulmonary fibrosis, scleroderma, radiation‐induced pulmonary fibrosis, and asthma. Furthermore, activation of profibrotic TGF‐β signaling has a central role in glucose‐induced cell hypertrophy, induces glucose transporter 1, and regulates mitochondrial energetics. However, the mechanisms by which TGF‐β induces specific metabolic alterations in the fibrogenic process have not been fully defined. In this study, we demonstrate that TGF‐β stimulates type I TGF β receptor (TβRI) translocation to the mitochondria and induction of hexokinase 2 (HK2) via both Smad‐dependent and –independent pathways. Also, we showed that TbRI association with HK2 and the mitochondrial voltage‐dependent ion channel (VDAC). These findings suggest that TβRI plays a novel role in controlling mitochondrial function and regulation of glucose metabolism. Support or Funding Information This work was supported by Public Health Service grants GM‐055816 and GM‐054200 from the National Institutes of General Medical Sciences. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Standardizing nomenclature in regional anesthesia: an ASRA-ESRA Delphi consensus study of abdominal wall, paraspinal, and chest wall blocks
El‐Boghdadly, Kariem , Wolmarans, Morné , Stengel, Angela D , Albrecht, Éric , Chin, Ki Jinn , Elsharkawy, Hesham , Kopp, Sandra L. , Mariano, Edward R. , Xu, Jeff L. , Adhikary, Sanjib Das , Barrington, Michael J. , Blanco, Rafael, Boretsky, Karen , Breebaart, Margaretha , Laurent, David Burckett-St , Carvalho, Brendan , Chuan, Alwin , Coppens, Steve , Costache, I. , Dam, Mette , Egeler, C., Pérez, Mario Fajardo , Gadsden, Jeff, Gautier, Philippe , Grant, Stuart A. , Hadžić, Admir , Hebbard, Peter , Hernandez, Nadia , Hogg, Rosemary , Holtz, Margaret, Kessler, Paul, Kwofie, Kwesi , Lobo, Clara , Ludwin, Danielle, Macfarlane, Alan , McDonnell, John G., McLeod, Graeme , Merjavy, Peter , Moran, EML , OʼDonnell, Brian D. , Parras, Teresa, Pawa, Amit , Perlas, Anahi , Gomez, Maria Fernanda Rojas , Saporito, Andrea , Sinha, Sanjay K. , Thottungal, Athmaja , Tsui, Ban C. H. , Tulgar, Serkan , Turbitt, Lloyd , Uppal, Vishal , Geffen, Geert J. van, Volk, Thomas , Elkassabany, Nabil , Kopp, Sandra , Altıparmak, Başak , Bloc, Sébastien , Børglum, Jens , Chuan, Alwin , Dam, Mette , Johnson, Rebecca L , Karmakar, Manoj Kumar , McLeod, Graeme , Pawa, Amit , Perlas, Anahi , Soffin, Ellen M , Tsui, Ban C H , Tulgar, Serkan , Uppal, Vishal , Mariano, Edward R , El-Boghdadly, K , Adhikary, Sanjib , Macfarlane, Alan James Robert , Volk, Thomas , Lobo, Clara , Carvalho, Brendan , Chin, Ki Jinn , Kwofie, M Kwesi , Stengel, Angela , Albrecht, Eric , Coppens, Steve , Blanco, Rafael, Capdevila, Xavier , Johnson, Rebecca L. , Kessler, Paul, Sala‐Blanch, Xavier , Soffin, Ellen M.

Mayo Clinic

Regional Anesthesia & Pain Medicine | June 18, 2021 | Volume: 46 | Issue: 7 | Pages: 571-580

10.1136/rapm-2020-102451 | PMID 34145070 Get It

Background There is heterogeneity in the names and anatomical descriptions of regional anesthetic techniques. This may have adverse consequences on education, research, and implementation into clinical practice. We aimed to produce standardized nomenclature for abdominal wall, paraspinal, and chest wall regional anesthetic techniques. Methods We conducted an international consensus study involving experts using a three-round Delphi method to produce a list of names and corresponding descriptions of anatomical targets. After long-list formulation by a Steering Committee, the first and second rounds involved anonymous electronic voting and commenting, with the third round involving a virtual round table discussion aiming to achieve consensus on items that had yet to achieve it. Novel names were presented where required for anatomical clarity and harmonization. Strong consensus was defined as ≥75% agreement and weak consensus as 50% to 74% agreement. Results Sixty expert Collaborators participated in this study. After three rounds and clarification, harmonization, and introduction of novel nomenclature, strong consensus was achieved for the names of 16 block names and weak consensus for four names. For anatomical descriptions, strong consensus was achieved for 19 blocks and weak consensus was achieved for one approach. Several areas requiring further research were identified. Conclusions Harmonization and standardization of nomenclature may improve education, research, and ultimately patient care. We present the first international consensus on nomenclature and anatomical descriptions of blocks of the abdominal wall, chest wall, and paraspinal blocks. We recommend using the consensus results in academic and clinical practice.
Diagnosis and Treatment of Femoral Head Osteonecrosis: A Protocol for Development of Evidence-Based Clinical Practice Guidelines
Cui, Quanjun , Baek, Seung‐Hoon , Drescher, Wolf , Hernigou, Philippe , Jones, Lynne C. , Koo, Kyung‐Hoi , Lee, Mel, Mont, Michael A. , Reichert, Ines , Salem, Hytham S. , Stronach, Ben M., Sugano, Nobuhiko , Zhao, Dewei , Cheng, Edward Y. , Goodman, Stuart B. , Ando, Wataru , Bakker, Caitlin , Kim, Harry K.W. , Kim, Shin‐Yoon , Kim, Tae-Young , Ha, Yong‐Chan , Sakai, Takashi , Sierra, Rafael J. , Yamamoto, Takuaki , Yoon, Byung‐Ho

Mayo Clinic

Surgical Technology Online | June 14, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.52198/21.sti.38.os1437 | PMID 34043232 Get It

Introduction: There are many treatment options for patients who have osteonecrosis of the femoral head (ONFH) and management strategies vary widely both among and within individual countries. Although many researchers have attempted to elucidate the optimal strategies for managing this disease, the lack of large-scale randomized control trials and the lack of agreement on disease staging have curtailed the development of clear-cut guidelines. Materials and Methods: The Association Research Circulation Osseous (ARCO) group sought to address three questions for the management of patients who have ONFH: 1) What imaging studies are most sensitive and specific for the diagnostic evaluation of patients who have ONFH?; 2) What is the best treatment strategy for preventing disease progression in patients who have pre-collapse lesions?; and 3) What is the best treatment strategy for patients who have post-collapse disease? The Patient, Intervention, Comparison, and Outcome (PICO) format was used to formulate the search strategy for each research question. A systematic review will be performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. ARCO participants have been allocated to three groups, each representing one of the PICO questions. After qualitative and quantitative analysis of the data extracted from studies pertaining to each of the three research questions, a set of evidence-based clinical practice guidelines will be proposed for the management of patients who have ONFH. Discussion: It is not always clear which treatment method is optimal for the management of ONFH. Thus, many surgeons have developed and performed various procedures based on patient-specific factors. As there is no consensus on the optimal treatment for various stages of disease, it was clear that developing evidence-based clinical practice guidelines would provide more structure and uniformity to management of these patients. Therefore, the results of this systematic review will lead to the development guidelines that may improve patient-care strategies and result in better outcomes for patients who have ONFH.
Super-Refractory Status Epilepticus in Children: A Retrospective Cohort Study
Vasquez, Alejandra , Farias‐Moeller, Raquel , Sánchez-Fernández, Iván, Amengual‐Gual, Marta , Anderson, Anne E. , Brenton, J. Nicholas , Carpenter, Jessica L. , Chapman, Kevin , Clark, Justice , Gaillard, William D. , Goldstein, Joshua , Goodkin, Howard P. , McDonough, Tiffani L. , Mikati, Mohamad A. , Morgan, Lindsey A. , Ostendorf, Adam P. , Payne, Eric T. , Peariso, Katrina , Piantino, Juan , Riviello, James J. , Sands, Tristan T. , Sannagowdara, Kumar , Tasker, Robert C. , Topjian, Alexis , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, Brenton, J Nicholas , Tasker, Robert C , Wainwright, Mark S , Gaillard, William D , Mikati, Mohamad A , Morgan, Lindsey A , Abend, Nicholas S. , Arya, Ravindra , Glauser, Tracy A. , Guerriero, Rejean M , Lai, Yi‐Chen , Novotny, Edward J. , Tchapyjnikov, Dmitry , Loddenkemper, Tobias

Mayo Clinic

Pediatric Critical Care Medicine | June 14, 2021 | Volume: 22 | Issue: 12 | Pages: e613-e625

10.1097/pcc.0000000000002786 | PMID 34120133 Get It

OBJECTIVES: To characterize the pediatric super-refractory status epilepticus population by describing treatment variability in super-refractory status epilepticus patients and comparing relevant clinical characteristics, including outcomes, between super-refractory status epilepticus, and nonsuper-refractory status epilepticus patients. DESIGN: Retrospective cohort study with prospectively collected data between June 2011 and January 2019. SETTING: Seventeen academic hospitals in the United States. PATIENTS: We included patients 1 month to 21 years old presenting with convulsive refractory status epilepticus. We defined super-refractory status epilepticus as continuous or intermittent seizures lasting greater than or equal to 24 hours following initiation of continuous infusion and divided the cohort into super-refractory status epilepticus and nonsuper-refractory status epilepticus groups. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We identified 281 patients (157 males) with a median age of 4.1 years (1.3–9.5 yr), including 31 super-refractory status epilepticus patients. Compared with nonsuper-refractory status epilepticus group, super-refractory status epilepticus patients had delayed initiation of first nonbenzodiazepine-antiseizure medication (149 min [55–491.5 min] vs 62 min [33.3–120.8 min]; p = 0.030) and of continuous infusion (495 min [177.5–1,255 min] vs 150 min [90–318.5 min]; p = 0.003); prolonged seizure duration (120 hr [58–368 hr] vs 3 hr [1.4–5.9 hr]; p < 0.001) and length of ICU stay (17 d [9.5–40 d] vs [1.8–8.8 d]; p < 0.001); more medical complications (18/31 [58.1%] vs 55/250 [22.2%] patients; p < 0.001); lower return to baseline function (7/31 [22.6%] vs 182/250 [73.4%] patients; p < 0.001); and higher mortality (4/31 [12.9%] vs 5/250 [2%]; p = 0.010). Within the super-refractory status epilepticus group, status epilepticus resolution was attained with a single continuous infusion in 15 of 31 patients (48.4%), two in 10 of 31 (32.3%), and three or more in six of 31 (19.4%). Most super-refractory status epilepticus patients (30/31, 96.8%) received midazolam as first choice. About 17 of 31 patients (54.8%) received additional treatments. CONCLUSIONS: Super-refractory status epilepticus patients had delayed initiation of nonbenzodiazepine antiseizure medication treatment, higher number of medical complications and mortality, and lower return to neurologic baseline than nonsuper-refractory status epilepticus patients, although these associations were not adjusted for potential confounders. Treatment approaches following the first continuous infusion were heterogeneous, reflecting limited information to guide clinical decision-making in super-refractory status epilepticus.